TNO innovation for life

TNO is an independent research organisation that conducts contract research, offers specialist consulting services, and grants licences for patents and specialist software.

Early patient involvement is key to develop digital outcome measures that matter. It will lead to outcomes that truly support value-based healthcare for diabetes and chronic diseases in general.

— Willem van den Brink, Scientist, TNO



- Diabetes management mostly targets HbA1c reduction, while the outcomes that patients tell us matter most to them are often related to complications such as heart failure, chronic kidney disease, and retinopathy.
- Our pre-competitive ENGAGE project proposal targets the identification and development of digital outcome measures beyond HbA1c, including micro- and macrovascular complications.



- We plan to use DiMe's Measures that Matter framework in focus groups and surveys among patients and providers to identify the meaningful aspects of health, concepts of interest, and digital outcome measures related to Type 2 diabetes.
- Together with patients, pharma, medtech, providers, and payers, we will work out use cases utilizing the digital outcome measures targeting real-world evidence generation, shared decision making, and disease self-management.



The Impact

✓ The framework helps structure our proposition towards the identification and development of digital outcome measures in a truly patient-centric approach.